Investigational drug · Phase 2
RMC-6291
Also called: Elironrasib
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "RMC-6291"
First trial start
2023
Nov 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RMC-6291", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer, NSCLC
- KRAS, NRAS, HRAS-mutated NSCLC
- KRAS G12C-mutated Solid Tumors, Lung Cancer
- Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
- RAS G12D-mutated NSCLC
- Advanced Solid Tumors
- Metastatic Solid Tumors
- Non-small Cell Lung Cancer (NSCLC)
- NSCLC
- Colorectal Cancer (CRC)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "RMC-6291" as an intervention, largest first.
Revolution Medicines, Inc.Industry
NCT06162221 · 616 participants (planned) · Start Jan 18, 2024 · Primary completion Jun 2027
Drug: RMC-6291; RMC-6236 and 5 more · For: Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer and 2 more
Sites: Gilbert, Arizona; Duarte, California; Irvine, California · 98 sites in all
Revolution Medicines, Inc.Industry
NCT06128551 · 534 participants (planned) · Start Nov 14, 2023 · Primary completion Dec 2028
Drug: Elironrasib; Daraxonrasib · For: Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer; Pancreatic Ductal Adenocarcinoma
Sites: Duarte, California; Orange, California; Sacramento, California · 56 sites in all
- Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsActive, not recruiting
Revolution Medicines, Inc.Industry
NCT05462717 · 222 participants (planned) · Start Sep 19, 2022 · Primary completion Mar 31, 2027
Drug: RMC-6291 · For: Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma and 1 more
Sites: Springdale, Arkansas; Orange, California; Sacramento, California · 64 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Rapid target engagement of KRAS G12C tricomplex inhibitor RO3903 overcomes resistance and drives durable tumor regression.
Yao X, Wang S, Xie J, et al. · Proc Natl Acad Sci U S A 2026
- Variant-Selective and Pan-RAS Inhibitors Enhance Targeted Agent Activity in Patient-Derived Multi-cell-type Tumor Spheroids.
Dexheimer TS, Davoudi Z, Coussens NP, et al. · Mol Cancer Ther 2026
- Evolution of KRAS molecular glues: from allele-selective to Pan-RAS and protein-protein interaction modulators.
Xiao XZ, Wang YJ, Pang XF, et al. · Acta Pharmacol Sin 2026
- KRAS in pancreatic cancer: from molecular biology to transformative therapeutics.
Abdelhakeem A, Ganatra N, Gul K, et al. · J Hematol Oncol 2026
- Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids.
Dexheimer TS, Davoudi Z, Coussens NP, et al. · Mol Cancer Ther 2026
- Activity and specificity of KRAS variants-directed Revolution Medicines Company (RMC) compounds for pleural effusion-derived non-small cell lung cancer cell lines.
Stickler S, Eggerstorfer MT, Rieche M, et al. · Transl Lung Cancer Res 2026
Also in development for Non-Small Cell Lung Cancer, NSCLC
- RMC-9805Phase 23 trials
Revolution Medicines, Inc. · PDAC, Colorectal Cancer, CRC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.